Cardio Diagnostics (NASDAQ:CDIO) and Response Genetics (OTCMKTS:RGDXQ) Head to Head Review

Cardio Diagnostics (NASDAQ:CDIO) and Response Genetics (OTCMKTS:RGDXQ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Cardio Diagnostics and Response Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-22,777.20%	-258.85%	-191.20%
Response Genetics	N/A	N/A	N/A

Institutional & Insider Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 4.9% of Response Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cardio Diagnostics and Response Genetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$20,000.00	614.49	-$8.38 million	N/A	N/A
Response Genetics	N/A	N/A	N/A	N/A	N/A

Response Genetics has lower revenue, but higher earnings than Cardio Diagnostics.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cardio Diagnostics and Response Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0	0	1	0	3.00
Response Genetics	0	0	0	0	0.00

Cardio Diagnostics currently has a consensus target price of $2.00, indicating a potential upside of 558.11%. Given Cardio Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Response Genetics.

Summary

Cardio Diagnostics beats Response Genetics on 6 of the 9 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.